243 related articles for article (PubMed ID: 31729189)
1. Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials.
Chen YC; Yoo DH; Lee CK; Li KJ; Won JE; Wu WS; Zhong J; Nicolay C; Walls CD; Tanaka Y
Int J Rheum Dis; 2020 Jan; 23(1):65-73. PubMed ID: 31729189
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials.
Harigai M; Takeuchi T; Smolen JS; Winthrop KL; Nishikawa A; Rooney TP; Saifan CG; Issa M; Isaka Y; Akashi N; Ishii T; Tanaka Y
Mod Rheumatol; 2020 Jan; 30(1):36-43. PubMed ID: 30784354
[No Abstract] [Full Text] [Related]
3. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
Smolen JS; Genovese MC; Takeuchi T; Hyslop DL; Macias WL; Rooney T; Chen L; Dickson CL; Riddle Camp J; Cardillo TE; Ishii T; Winthrop KL
J Rheumatol; 2019 Jan; 46(1):7-18. PubMed ID: 30219772
[TBL] [Abstract][Full Text] [Related]
4. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
[TBL] [Abstract][Full Text] [Related]
5. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
[TBL] [Abstract][Full Text] [Related]
6. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
Winthrop KL; Harigai M; Genovese MC; Lindsey S; Takeuchi T; Fleischmann R; Bradley JD; Byers NL; Hyslop DL; Issa M; Nishikawa A; Rooney TP; Witt S; Dickson CL; Smolen JS; Dougados M
Ann Rheum Dis; 2020 Oct; 79(10):1290-1297. PubMed ID: 32788396
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.
Taylor PC; Weinblatt ME; Burmester GR; Rooney TP; Witt S; Walls CD; Issa M; Salinas CA; Saifan C; Zhang X; Cardoso A; González-Gay MA; Takeuchi T
Arthritis Rheumatol; 2019 Jul; 71(7):1042-1055. PubMed ID: 30663869
[TBL] [Abstract][Full Text] [Related]
8. Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study.
Wu CY; Wang Q; Shi J; Zhang XY; Du R; Gu JR; Liu QH; Yu J; Xu JW; Zhang YJ; Zhu H; Li MT; Zeng XF
Rheumatol Ther; 2023 Dec; 10(6):1609-1622. PubMed ID: 37768505
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.
Tanaka Y; Atsumi T; Amano K; Harigai M; Ishii T; Kawaguchi O; Rooney TP; Akashi N; Takeuchi T
Mod Rheumatol; 2018 Jul; 28(4):583-591. PubMed ID: 29134891
[TBL] [Abstract][Full Text] [Related]
10. The safety of baricitinib in patients with rheumatoid arthritis.
Honda S; Harigai M
Expert Opin Drug Saf; 2020 May; 19(5):545-551. PubMed ID: 32174196
[No Abstract] [Full Text] [Related]
11. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis.
Genovese MC; Smolen JS; Takeuchi T; Burmester G; Brinker D; Rooney TP; Zhong J; Daojun M; Saifan C; Cardoso A; Issa M; Wu WS; Winthrop KL
Lancet Rheumatol; 2020 Jun; 2(6):e347-e357. PubMed ID: 38273598
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
Tanaka Y; Fautrel B; Keystone EC; Ortmann RA; Xie L; Zhu B; Issa M; Patel H; Gaich CL; de Bono S; Rooney TP; Taylor PC
Ann Rheum Dis; 2019 Jul; 78(7):890-898. PubMed ID: 31040122
[TBL] [Abstract][Full Text] [Related]
13. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials.
Bieber T; Thyssen JP; Reich K; Simpson EL; Katoh N; Torrelo A; De Bruin-Weller M; Thaci D; Bissonnette R; Gooderham M; Weisman J; Nunes F; Brinker D; Issa M; Holzwarth K; Gamalo M; Riedl E; Janes J
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):476-485. PubMed ID: 32926462
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
Keystone EC; Taylor PC; Drescher E; Schlichting DE; Beattie SD; Berclaz PY; Lee CH; Fidelus-Gort RK; Luchi ME; Rooney TP; Macias WL; Genovese MC
Ann Rheum Dis; 2015 Feb; 74(2):333-40. PubMed ID: 25431052
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study.
Tanaka Y; Ishii T; Cai Z; Schlichting D; Rooney T; Macias W
Mod Rheumatol; 2018 Jan; 28(1):20-29. PubMed ID: 28440680
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy.
Winthrop KL; Bingham CO; Komocsar WJ; Bradley J; Issa M; Klar R; Kartman CE
Arthritis Res Ther; 2019 Apr; 21(1):102. PubMed ID: 30999933
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
Cohen SB; Tanaka Y; Mariette X; Curtis JR; Lee EB; Nash P; Winthrop KL; Charles-Schoeman C; Wang L; Chen C; Kwok K; Biswas P; Shapiro A; Madsen A; Wollenhaupt J
RMD Open; 2020 Oct; 6(3):. PubMed ID: 33127856
[TBL] [Abstract][Full Text] [Related]
18. Risk of Adverse Drug Events Observed with Baricitinib 2 mg Versus Baricitinib 4 mg Once Daily for the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Huang F; Luo ZC
BioDrugs; 2018 Oct; 32(5):415-423. PubMed ID: 30203252
[TBL] [Abstract][Full Text] [Related]
19. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials.
Bieber T; Katoh N; Simpson EL; de Bruin-Weller M; Thaçi D; Torrelo A; Sontag A; Grond S; Issa M; Lu X; Cardillo T; Holzwarth K; Thyssen JP
J Dermatolog Treat; 2023 Dec; 34(1):2161812. PubMed ID: 36546346
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis.
Keystone EC; Genovese MC; Schlichting DE; de la Torre I; Beattie SD; Rooney TP; Taylor PC
J Rheumatol; 2018 Jan; 45(1):14-21. PubMed ID: 28811354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
